Indian Journal of Endocrinology and Metabolism

REVIEW ARTICLE
Year
: 2012  |  Volume : 16  |  Issue : 7  |  Page : 20--26

Pathogenesis and treatment of human immunodeficiency virus lipodystrophy


Suyog Subhash Jain1, Karuna Balwant Ramteke1, Girish Tulsidas Raparti1, Sanjay Kalra2 
1 Department of Pharmacology, Government Medical College, Miraj, Maharashtra, India
2 Department of Endocrinology, Bharti Hospital and B.R.I.D.E., Karnal, India

Correspondence Address:
Suyog Subhash Jain
Department of Pharmacology, Government Medical College, Miraj-416410, Maharashtra
India

Enhanced understanding about the way human immunodeficiency virus (HIV) infects and causes infection in humans has led to invention and use of newer more effective antiretroviral drugs. As treatment for HIV is long term, side effects of the antiretrovirals become an important area of research focus. Antiretrovirals can cause severe metabolic abnormalities, collectively known as HIV lipodystrophy syndrome. If untreated, these metabolic abnormalities have the potential to increase stroke and cardiac ischemia. Management includes choice of nonoffending drugs, switch over to less toxic drugs, hypolipidemics, oral antidiabetics including thiazolidinediones, metformin and growth hormone analogs and finally facial surgeries. Updated knowledge about HIV lipodystrophy, and the hormone-related drugs used to treat it, is essential for physicians and endocrinologists to be able to diagnose the patients and effectively treat them.


How to cite this article:
Jain SS, Ramteke KB, Raparti GT, Kalra S. Pathogenesis and treatment of human immunodeficiency virus lipodystrophy.Indian J Endocr Metab 2012;16:20-26


How to cite this URL:
Jain SS, Ramteke KB, Raparti GT, Kalra S. Pathogenesis and treatment of human immunodeficiency virus lipodystrophy. Indian J Endocr Metab [serial online] 2012 [cited 2021 Apr 14 ];16:20-26
Available from: https://www.ijem.in/article.asp?issn=2230-8210;year=2012;volume=16;issue=7;spage=20;epage=26;aulast=Jain;type=0